Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Nexstim Plc: Proposals of the Shareholder’s Nomination Board to the Annual General Meeting | ||
By: GlobeNewswire - 30 Jan 2023 | Back to overview list |
|
Company announcement, Helsinki, 30 January 2023 at 9:30 AM (EET) Nexstim Plc: Proposals of the Shareholder’s Nomination Board to the Annual General Meeting The Shareholder’s Nomination Board of Nexstim Corporation (NXTMH: HEX, NXTMS: STO) (“Nexstim” or the “Company”) has on 26 January 2023 in its meeting resolved its proposal to the Annual General Meeting of Nexstim, which will be held on Friday March 31, 2023. The Nomination Board of Shareholders representing the largest shareholders proposes to the Annual General Meeting that:
The Nomination Board acknowledged, that Leena Niemistö is independent from the company but not in respect of the shareholders of the company as she and a company called Kaikarhenni Oy of which she holds a controlling majority, jointly hold approximately 15,45 % (as of 26.1.2023) of all registered shares and votes in the company. Other proposed members are independent both from the company and its major shareholders. It is the collective opinion of the Nomination Committee that the proposed new members of the Board of Directors and the Board of Directors in its entirety are suitable for the assignment both collectively and individually and that Leena Niemistö is suitable for the position as Chair of the Board of Directors. The Nomination Board proposes that the members of the Board of Directors chosen in the Annual General Meeting be remunerated for the period ending at the end of the 2024 Annual General Meeting as follows:
According to the company’s policy, the cash remuneration is paid in four instalments. The purpose of the option plan to be established is to commit the participants to the company, to combine the objectives of the shareholders and participants and thus to increase the value of the company. Ownership Recommendation The Shareholders Nomination Board resolved to propose to the General Meeting of Shareholders that
Travelling expenses The Nomination Board resolved to propose to the General Meeting of Shareholders that
Helsinki, January 30, 2023 NEXSTIM PLC Nomination Board of the Shareholders Further information is available on the website www.nexstim.com or by contacting: Leena Niemistö, Chair of the Nomination Board The Company’s Certified Advisor is Erik Penser Bank. About Nexstim Plc Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders. Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain. Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim’s Therapy Business markets and sells the Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden. For more information, please visit www.nexstim.com Attachment |
||
|
||
Copyright 2023 GlobeNewswire | Back to overview list |